Lepzacitinib

Catalog No. :
ACOSIK549
CAS No. :
2321488-47-3
Molecular Formula :
C18H21N5O3
Molecular Weight :
355.40

IUPAC Name:ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate

Lepzacitinib structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$84.00Login to see priceIn stockInquiry
10mg98%$134.00Login to see priceIn stockInquiry
25mg98%$268.00Login to see priceIn stockInquiry
50mg98%$454.00Login to see priceIn stockInquiry
100mg98%$773.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameLepzacitinib
IUPAC Nameethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate
Molecular FormulaC18H21N5O3
Molecular Weight355.40
SMILESO=C(C1=CN=C(NC=C2)C2=C1N[C@H]3CN(C(CC#N)=O)CCC3)OCC
InChI KeyQQOPOYMFJLUSBI-GFCCVEGCSA-N
SynonymLepzacitinib;1H-Pyrrolo[2,3-b]pyridine-5-carboxylic acid, 4-[[(3R)-1-(2-cyanoacetyl)-3-piperidinyl]amino]-, ethyl ester
CAS No.2321488-47-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACOSIK549 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMCAP915 route compound structure diagram
    ACMCAP9151071-36-9 In Stock
  4. Then
  5. ACOSIK549 route product structure diagram
    ACOSIK5492321488-47-3 In Stock
Inquiry

2. ACOSIK549 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOSIK549 route product structure diagram
    ACOSIK5492321488-47-3 In Stock
Inquiry

Comments (0)